Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New dopaminergic agonists].

J P de Mattos1, V M Mattos

  • 1Serviço de Neurologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro (UFRJ), Brasil.

Arquivos De Neuro-Psiquiatria
|July 21, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eyelid dystonia in Machado-Joseph disease.

Movement disorders : official journal of the Movement Disorder Society·2000
Same author

[Tic disease. Current genetic and neurochemical factors].

Arquivos de neuro-psiquiatria·1999
Same author

[Differential diagnosis of tremors].

Arquivos de neuro-psiquiatria·1998
Same author

[Dementia in Parkinson's disease. Critical evaluation of the literature].

Arquivos de neuro-psiquiatria·1996
Same author

[Dystonias: clinical and therapeutic aspects in 64 patients].

Arquivos de neuro-psiquiatria·1996
Same author

Spinal cord compression due to extramedullary hematopoiesis in the proliferative phase of polycythemia vera.

Acta haematologica·1996
Same journal

Prevalence and predictors of low bone mineral density in Myasthenia gravis.

Arquivos de neuro-psiquiatria·2026
Same journal

Hypochondriasis, somatic amplification, and pain beliefs in patients with medication overuse headache.

Arquivos de neuro-psiquiatria·2026
Same journal

Ozzy Osbourne and Parkinson's disease: from darkness to awareness.

Arquivos de neuro-psiquiatria·2026
Same journal

The weight of genotype on the clinical presentation of COQ7-related hereditary motor axonal neuropathy: a case series and literature review.

Arquivos de neuro-psiquiatria·2026
Same journal

Rituximab as a sustainable high-efficacy solution for multiple Sclerosis in Brazil.

Arquivos de neuro-psiquiatria·2026
Same journal

Reply to: "Sleep quality is influenced by multiple factors and cannot be reduced to the volume of pineal gland calcification".

Arquivos de neuro-psiquiatria·2026
See all related articles

Dopaminergic agonists offer an alternative to levodopa for Parkinson's disease, managing limitations and extending therapeutic benefits. This review analyzes key agonists like cabergoline, ropinirole, and pramipexole, detailing their efficacy and side effects.

Area of Science:

  • Neuroscience
  • Pharmacology

Context:

  • Parkinson's disease is a neurodegenerative disorder primarily affecting motor function.
  • Levodopa is a common treatment, but its efficacy can be limited over time.

Purpose:

  • To review the literature on dopaminergic agonists for Parkinson's disease.
  • To analyze the pharmacokinetic efficacy and side effects of specific dopaminergic agonists: cabergoline, ropinirole, and pramipexole.

Summary:

  • Dopaminergic agonists are introduced to overcome levodopa limitations and widen the therapeutic window in Parkinson's patients.
  • The review details the five known dopaminergic receptors, their locations, and the pros and cons of using agonists.
  • Pharmacokinetic profiles and adverse effects of cabergoline, ropinirole, and pramipexole are analyzed.

Related Experiment Videos

Impact:

  • Provides a comprehensive overview of dopaminergic agonists for Parkinson's disease management.
  • Aids clinicians in selecting appropriate dopaminergic agonists based on efficacy and side effect profiles.
  • Contributes to understanding treatment strategies for improving motor control and quality of life in Parkinson's patients.